Sharing Concept-to-Clinic Development of Myeloid Checkpoint Inhibitors

Time: 9:30 am
day: Day One


  • Reprogramming myeloid cells with myeloid checkpoint inhibitor antibodies to diminish inhibitory signals and halt the immune suppressive activity of myeloid cells in solid tumors
  • Outlining the impact of checkpoint inhibition on multiple myeloid cell subsets, including dendritic cells, tumor-associated macrophages, monocytes, and neutrophils
  • Demonstrating the specific and non-redundant role of LILRB myeloid checkpoints